HPV detection methods

Disease Markers

Volumn 23, Issue 4, 2007, Pages 273-281

  Brink, Antoinette A T P ^a   Snijders, Peter J F ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical carcinoma; DNA probes; Epidemiology; Human papillomavirus; Hybrid capture; NASBA; Polymerase chain reaction; Real time PCR; Reverse hybridization

Indexed keywords

MESSENGER RNA; WART VIRUS VACCINE;

ALGORITHM; CANCER PATIENT; CANCER SCREENING; CYTOLOGY; DISEASE SEVERITY; GENE AMPLIFICATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; NONHUMAN; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 34347352264     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/147429     Document Type: Review

References (81)

1. A.T. Lorincz and R.M. Richart, Human Papillomavirus DNA Testing as an Adjunct to Cytology in Cervical Screening Programs, Arch Pathol Lab Med 127 (2003), 959-968.
2. J. Cuzick, A. Szarewski, H. Cubie et al., Management of women who test positive for high-risk types of human papillomavirus: the HART study, Lancet 362 (2003), 1871-1876.
3. A.G. Bais, M. Rebolj, P.J. Snijders et al., Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines, Int J Cancer 116 (2005), 122-129.
4. G.D. Zielinski, A.G. Bais, T.J. Helmerhorst et al., HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis, Obstet Gynecol Surv 59 (2004), 543-553.
5. M. Scheffner, B.A. Werness, J.M. Huibregtse, A.J. Levine and P.M. Howley, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell 63 (1990), 1129-1136.
6. N. Dyson, P.M. Howley, K. Munger and E. Harlow, The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product, Science 243 (1989), 934-937.
7. F.X. Bosch, A. Lorincz, N. Munoz, C.J. Meijer and K.V. Shah, The causal relation between human papillomavirus and cervical cancer, J Clin Pathol 55 (2002), 244-265.
8. N. Munoz, F.X. Bosch, S. de Sanjose et al., Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med 348 (2003), 518-527.
9. E.M. de Villiers, C. Fauquet, T.R. Broker, H.U. Bernard and H. zur Hausen, Classification of papillomaviruses, Virology 324 (2004), 17-27.
10. B.A. Werness, A.J. Levine and P.M. Howley, Association of human papillomavirus types 16 and 18 E6 proteins with p53, Science 248 (1990), 76-79.
11. J.R. Gage, C. Meyers and F.O. Wettstein, The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties, J Virol 64 (1990), 723-730.
12. Y. Kirii and T. Matsukura, Nucleotide sequence and phylogenetic classification of human papillomavirus type 67, Virus Genes 17 (1998), 117-121.
13. N. Munoz, F.X. Bosch, X. Castellsague et al., Against which human papillomavirus types shall we vaccinate and screen? The international perspective, Int J Cancer 111 (2004), 278-285.
14. M. Schiffman, M.J. Khan, D. Solomon et al., A study of the impact of adding HPV types to cervical cancer screening and triage tests, J Natl Cancer Inst 97 (2005), 147-150.
15. D.A. Galloway, Papillomavirus vaccines in clinical trials, Lancet Infect Dis 3 (2003), 469-475.
16. A.H. Beskow, M. Moberg and U.B. Gyllensten, HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri, Int J Cancer 117 (2005), 510-514.
17. A.H. Beskow and U.B. Gyllensten, Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri, Int J Cancer 101 (2002), 526-531.
18. N.W.J. Bulkmans, L. Rozendaal, P.J. Snijders et al., POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening; Design, methods and baseline data of 44,102 women, Int J Cancer 110 (2003), 94-101.
19. N.W. Bulkmans, M.C. Bleeker, J. Berkhof et al., Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse, Int J Cancer 117 (2005), 177-181.
20. S. Bulk, J. Berkhof, N.W. Bulkmans et al., Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands, Br J Cancer 94 (2006), 171-175.
21. M.J. Khan, P.E. Castle, A.T. Lorincz et al., The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst 97 (2005), 1072-1079.
22. P.E. Castle, D. Solomon, M. Schiffman and C.M. Wheeler, Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, J Natl Cancer Inst 97 (2005), 1066-1071.
23. P.E. Gravitt, C.L. Peyton, R.J. Apple and C.M. Wheeler, Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method, J Clin Microbiol 36 (1998), 3020-3027.
24. L.M. Tieben, J. ter Schegget, R.P. Minnaar et al., Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers, J Virol Methods 42 (1993), 265-279.
25. A.J. van den Brule, R. Pol, N. Fransen-Daalmeijer et al., GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes, J Clin Microbiol 40 (2002), 779-787.
26. L. Gregoire, M. Arella, J. Campione-Piccardo and W.D. Lancaster, Amplification of human papillomavirus DNA sequences by using conserved primers, J Clin Microbiol 27 (1989), 2660-2665.
27. B. Kleter, L.J. van Doorn, L. Schrauwen et al., Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus, J Clin Microbiol 37 (1999), 2508-2517.
28. P.E. Gravitt, C.L. Peyton, T.Q. Alessi et al., Improved amplification of genital human papillomaviruses, J Clin Microbiol 38 (2000), 357-361.
29. J. Monsonego, J.M. Bohbot, G. Pollini et al., Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) inwomen with abnormal PAP smear, Gynecol Oncol 99 (2005), 160-168.
30. M.V. Jacobs, P.J. Snijders, A.J. van den Brule et al., A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings, J Clin Microbiol 35 (1997), 791-795.
31. B. Kleter, L.J. van Doorn, J. ter Schegget et al., Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses, Am J Pathol 153 (1998), 1731-1739.
32. N.H. Cho, H.J. An, J.K. Jeong et al., Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis, Am J Obstet Gynecol 188 (2003), 56-62.
33. M. Schmitt, I.G. Bravo, P.J. Snijders et al., Bead-based multiplex genotyping of human papillomaviruses, J Clin Microbiol 44 (2006), 504-512.
34. O. Forslund, A. Antonsson, P. Nordin, B. Stenquist and B.G. Hansson, A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin, J Gen Virol 80(Pt 9) (1999), 2437-2443.
35. V. Shamanin, M. Glover, C. Rausch et al., Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients, Cancer Res 54 (1994), 4610-4613.
36. O. Lungu, T.C. Wright Jr. and S. Silverstein, Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis, Mol Cell Probes 6 (1992), 145-152.
37. K. Szuhai, E. Sandhaus, S.M. Kolkman-Uljee et al., A novel strategy for HPV detection and genotyping with SybrGreen and Molecular Beacon PCR, Am J Pathol 159 (2001), 1651-1660.
38. J.M. Walboomers, M.V. Jacobs, M.M. Manos et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol 189 (1999), 12-19.
39. A. Josefsson, K. Livak and U. Gyllensten, Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay, J Clin Microbiol 37 (1999), 490-496.
40. A.T. Hesselink, A.J. van den Brule, Z.M. Groothuismink et al., Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens, J Clin Microbiol 43 (2005), 4868-4871.
41. M. Moberg, I. Gustavsson and U. Gyllensten, Real-time PCRbased system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer, J Clin Microbiol 41 (2003), 3221-3228.
42. A.M. Josefsson, P.K. Magnusson, N. Ylitalo et al., Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study, Lancet 355 (2000), 2189-2193.
43. N. Ylitalo, P. Sorensen, A.M. Josefsson et al., Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study, Lancet 355 (2000), 2194-2198.
44. M. van Duin, P.J. Snijders, H.F. Schrijnemakers et al., Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance, Int J Cancer 98 (2002), 590-595.
45. P.J. Snijders, C.J. Hogewoning, A.T. Hesselink et al., Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology, Int J Cancer (2006).
46. P.J. Snijders, A.J. van den Brule and C.J. Meijer, The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity, J Pathol 201 (2003), 1-6.
47. K. Sotlar, A. Stubner, D. Diemer et al., Detection of highrisk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction, J Med Virol 74 (2004), 107-116.
48. H.L. Smits, B. van Gemen, R. Schukkink et al., Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts, J Virol Methods 54 (1995), 75-81.
49. K.S. Cuschieri, M.J. Whitley and H.A. Cubie, Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring, J Med Virol 73 (2004), 65-70.
50. I. Kraus, T. Molden, L.E. Erno et al., Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones, Br J Cancer 90 (2004), 1407-1413.
51. T. Molden, I. Kraus, F. Karlsen et al., Comparison of human papillomavirus messenger RNA and DNA detection: a crosssectional study of 4,136 women > 30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion, Cancer Epidemiol Biomarkers Prev 14 (2005), 367-372.
52. T. Molden, J.F. Nygard, I. Kraus et al., Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear, Int J Cancer 114 (2005), 973-976.
53. T. Molden, I. Kraus, F. Karlsen, H. Skomedal and B. Hagmar, Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age, Gynecol Oncol 100 (2005), 95-100.
54. R. Klaes, S.M. Woerner, R. Ridder et al., Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes, Cancer Res 59 (1999), 6132-6136.
55. N. Wentzensen, R. Ridder, R. Klaes et al., Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions, Oncogene 21 (2002), 419-426.
56. S. Vinokurova, N. Wentzensen, J. Einenkel et al., Clonal history of papillomavirus-induced dysplasia in the female lower genital tract, J Natl Cancer Inst 97 (2005), 1816-1821.
57. C. Clavel, M. Masure, I. Putaud et al., Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions, J Clin Pathol 51 (1998), 737-740.
58. P.E. Castle, M. Schiffman, R.D. Burk et al., Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types, Cancer Epidemiol Biomarkers Prev 11 (2002), 1394-1399.
59. M.N. Qureshi, R.D. Rudelli, R.R. Tubbs, C.V. Biscotti and L.J. Layfield, Role of HPV DNA testing in predicting cervical intraepithelial lesions: comparison of HC HPV and ISH HPV, Diagn Cytopathol 29 (2003), 149-155.
60. A.T. Hesselink, A.J. van den Brule, A.A. Brink et al., Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples, Cancer 102 (2004), 11-18.
61. A.H. Hopman, F. Smedts, W. Dignef et al., Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities, J Pathol 202 (2004), 23-33.
62. H.M. Kerstens, P.J. Poddighe and A.G. Hanselaar, A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine, J Histochem Cytochem 43 (1995), 347-352.
63. C.C. Impraim, R.K. Saiki, H.A. Erlich and R.L. Teplitz, Analysis of DNA extracted from formalin-fixed, paraffin-embedded tissues by enzymatic amplification and hybridization with sequence-specific oligonucleotides, Biochem Biophys Res Commun 142 (1987), 710-716.
64. R.J. Slebos, L. Boerrigter, S.G. Evers et al., A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues, Diagn Mol Pathol 1 (1992), 136-141.
65. Mattosinho de Castro Ferraz Mda, S.M. Nicolau, J.N. Stavale et al., Cervical biopsy-based comparison of a new liquid-based thin-layer preparation with conventional Pap smears, Diagn Cytopathol 30 (2004), 220-226.
66. N.S. Taha, J. Focchi, J.C. Ribalta et al., Universal Collection Medium (UCM) is as suitable as the Standard Transport Medium (STM) for Hybrid Capture II® (HC-2) assay, J Clin Virol 36 (2006), 32-35.
67. A.M. de Roda Husman, P.J. Snijders, H.V. Stel et al., Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction, Br J Cancer 72 (1995), 412-417.
68. T.A. Tarkowski, M.S. Rajeevan, D.R. Lee and E.R. Unger, Improved detection of viral RNA isolated from liquid-based cytology samples, Mol Diagn 6 (2001), 125-130.
69. A.K. Lie, B. Risberg, B. Borge et al., DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia, Gynecol Oncol 97 (2005), 908-915.
70. F. Lewis, N.J. Maughan, V. Smith, K. Hillan and P. Quirke, Unlocking the archive - gene expression in paraffin-embedded tissue, J Pathol 195 (2001), 66-71.
71. Digene Hybrid Capture 2 high-risk HPV DNA test - part 3 (Labelling). http://www.fda.gov/cdrh/pdf/P890064s009c.pdf, 2006.
72. M.N. Qureshi, D. Bolick, P.J. Ringer, F.L. Spagler and G. Zimmerman, HPV testing in liquid cytology specimens: comparison of analytic sensitivty and specificity for in situ hybridization and chemiluminescent nucleic acid testing, Acta Cytol 49 (2005), 120-126.
73. P. Vassilakos, P. Petignat, M. Boulvain and A. Campana, Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing, Br J Cancer 86 (2002), 382-388.
74. S. Davis-Devine, S.J. Day and G.G. Freund, Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method, Am J Clin Pathol 124 (2005), 24-30.
75. G.D. Zielinski, L. Rozendaal, F.J.Voorhorst et al., HPVtesting can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3, Gynecol Oncol 91 (2003), 67-73.
76. M.A. Nobbenhuis, C.J. Meijer, A.J. van den Brule et al., Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia, Br J Cancer 84 (2001), 796-801.
77. P. Hawley-Nelson, K.H. Vousden, N.L. Hubbert, D.R. Lowy and J.T. Schiller, HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes, EMBO J 8 (1989), 3905-3910.
78. K.B. Choo, C.C. Pan and S.H. Han, Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames, Virology 161 (1987), 259-261.
79. A.T. Hesselink, M. Lettink, J. Berkhof, C.J. Meijer and P.J. Snijders, Comparison of a novel consensus high-risk HPV E7 PCR with GP5+/6+ PCR on cervical scrapings. 2006. 6th International Multidisciplinary Congress on Human Papillomavirus Infection and Global Prevention of Cervical Cancer - EUROGIN. Monsonego, J. 23-4-2006.
80. L. Rozendaal, J. Westerga, J.C. van der Linden et al., PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes, J Clin Pathol 53 (2000), 606-611.
81. L. Rozendaal, J.M. Walboomers, J.C. van der Linden et al., PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears, Int J Cancer 68 (1996), 766-769.